Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound surged in the fourth quarter despite missing the company’s initial sales expectations. Zepbound sales reached $1.9 billion in ...

On an adjusted basis, the U.S. drugmaker expects to earn between $22.50 and $24.00 per share in 2025. Analysts were expecting ...

Plus, check out our handy semaglutide weight loss dosage chart for an easy-to-follow overview ... 1 receptor agonist to help with weight loss. Zepbound (tirzepatide) and Saxenda (liraglutide ...

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, as it prepares to launch its popular ...

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

Lange explained on a conference call that one reason for the miss was a flexible treatment protocol that allowed patients to ...

The company said last month that it expected to report sales of diabetes drug Mounjaro and weight-loss treatment Zepbound below analysts' expectations for a second quarter in a row. The US ...

The increase in weight loss with the higher dose was impressive, but still lower than has been achieved in clinical trials of Eli Lilly's rival obesity therapy Zepbound (tirzepatide), which helped ...

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...